Phreesia (PHR) to Release Quarterly Earnings on Wednesday

Phreesia (NYSE:PHR – Get Rating) will be posting its quarterly earnings results after the market closes on Wednesday, March 22nd. Analysts expect Phreesia to post earnings of ($0.78) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Phreesia Price Performance

Shares of NYSE PHR opened at $34.78 on Wednesday. The firm has a market cap of $1.83 billion, a PE ratio of -9.82 and a beta of 0.65. The firm has a fifty day moving average of $35.95 and a 200 day moving average of $30.10. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.94 and a current ratio of 3.94. Phreesia has a one year low of $13.19 and a one year high of $40.00.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on PHR. Citigroup raised shares of Phreesia from a “neutral” rating to a “buy” rating and set a $40.00 target price for the company in a report on Tuesday, December 13th. SVB Leerink upped their price objective on shares of Phreesia from $34.00 to $39.00 and gave the company an “outperform” rating in a report on Thursday, January 5th. Royal Bank of Canada upped their target price on shares of Phreesia from $22.00 to $26.00 and gave the company a “sector perform” rating in a research report on Friday, December 9th. KeyCorp upped their target price on shares of Phreesia from $40.00 to $45.00 and gave the company an “overweight” rating in a research report on Thursday, February 2nd. Finally, Needham & Company LLC upped their target price on shares of Phreesia from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, January 4th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, Phreesia has a consensus rating of “Moderate Buy” and a consensus price target of $37.07.

Insider Buying and Selling at Phreesia

In other news, SVP Michael J. Davidoff sold 28,555 shares of the firm’s stock in a transaction that occurred on Monday, January 30th. The shares were sold at an average price of $36.10, for a total transaction of $1,030,835.50. Following the transaction, the senior vice president now directly owns 108,749 shares in the company, valued at $3,925,838.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Phreesia news, SVP David Linetsky sold 11,378 shares of the firm’s stock in a transaction on Thursday, February 2nd. The stock was sold at an average price of $39.55, for a total value of $449,999.90. Following the completion of the sale, the senior vice president now owns 205,489 shares of the company’s stock, valued at $8,127,089.95. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Michael J. Davidoff sold 28,555 shares of the firm’s stock in a transaction on Monday, January 30th. The shares were sold at an average price of $36.10, for a total value of $1,030,835.50. Following the completion of the sale, the senior vice president now directly owns 108,749 shares of the company’s stock, valued at approximately $3,925,838.90. The disclosure for this sale can be found here. Insiders have sold 45,725 shares of company stock worth $1,707,595 over the last three months. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

A number of hedge funds and other institutional investors have recently bought and sold shares of PHR. Captrust Financial Advisors increased its position in Phreesia by 154.6% during the 2nd quarter. Captrust Financial Advisors now owns 1,426 shares of the company’s stock worth $36,000 after purchasing an additional 866 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Phreesia by 85.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,137 shares of the company’s stock worth $80,000 after purchasing an additional 1,445 shares in the last quarter. Point72 Hong Kong Ltd increased its position in Phreesia by 266.6% during the 1st quarter. Point72 Hong Kong Ltd now owns 5,381 shares of the company’s stock worth $142,000 after purchasing an additional 3,913 shares in the last quarter. UBS Group AG increased its position in Phreesia by 80.2% during the 2nd quarter. UBS Group AG now owns 7,787 shares of the company’s stock worth $195,000 after purchasing an additional 3,465 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in Phreesia in the 4th quarter valued at about $208,000. Institutional investors and hedge funds own 92.23% of the company’s stock.

About Phreesia

(Get Rating)

Phreesia, Inc is a healthcare software company, which engages in the provision of patient check-in solutions for medical practices. The firm offers appointments, clinical support, integration, registration, patient activation, analytics and reports, revenue cycle, patient surveys, and privacy and security products.